Solutions

Global Services. (Creative Biolabs Authorized)

Chimeric HLA Antibody Receptor (CHAR) Construction Service

Online Inquiry

Background Services What We Can Offer Required Starting Materials Workflow Advantages Customer Reviews FAQs Contact Us

Are you currently facing challenges in developing highly targeted immunotherapies, overcoming HLA-restricted responses, or engineering exquisitely specific cell therapies? Creative Biolabs' chimeric HLA antibody receptor (CHAR) construction service helps you overcome these limitations and engineer highly specific cell therapies through advanced genetic engineering and cell therapy design, accelerating your drug discovery process.

The Necessity of CHAR Construction

The landscape of gene therapy, particularly with CAR-T cells, has revolutionized cancer treatment. However, existing therapies often grapple with challenges such as on-target/off-tumor toxicity and the inherent HLA-restriction of T-cell receptors, limiting broader applicability. The necessity for developing novel approaches like CHARs is paramount to specifically target HLA-peptide complexes on diseased cells, broadening therapeutic windows and enabling precision targeting of intracellular antigens, thereby significantly enhancing safety and efficacy in various disease contexts.

Fig.1 Role of ligands in other antibody-mediated diseases. (OA Literature) Fig.1 Ligands play a role in antibody-mediated diseases.¹

Chimeric HLA Antibody Receptor (CHAR) Construction Service at Creative Biolabs

Creative Biolabs' CHAR construction service delivers engineered T-cells precisely targeting intracellular tumor-associated antigens (TAAs) presented by HLA. Enabling highly specific solid tumor immunotherapies, it overcomes traditional CAR-T limitations. Clients receive validated CHAR constructs, expanded T-cell targeting capabilities, and robust preclinical data to accelerate novel cancer therapeutics. We provide expert guidance from target selection to functional validation, leveraging cutting-edge technology for optimal outcomes—enhancing efficacy while minimizing off-target toxicities. Expect:

Custom design of optimized CHAR constructs (scFv, transmembrane, signaling domains) tailored to your antigen-HLA pair.
High-fidelity gene synthesis and vector cloning, ready for viral packaging.
Transduction and expansion of your immune cells, delivered at your required scale.
Comprehensive validation & quality control.
Flexible customization and rapid turnaround.

What we can offer

Analysis and testing of CHAR construction. (Creative Biolabs Original)

Whether you already have antigen and antibody sequence data or are starting from scratch, our team can guide you through each step - from concept to validated cell product.

Discover How We Can Help - Request a Consultation

Required Starting Materials

To initiate your CHAR construction project, we typically require:

Target Antigen Information: This includes the precise peptide sequence and the presenting HLA allele (e.g., HLA-A02:01, HLA-B07:02). Providing structural information of the peptide-MHC complex, if available, can further optimize design.
Desired Antibody Clone Information: We need the variable region sequences (VH and VL) of the antibody intended for the scFv component of the CHAR. If an antibody is not available, we can assist with discovery.
Vector Backbone Preferences: Any specific requirements for the lentiviral vector backbone (e.g., specific promoters, reporter genes) should be provided.

One-stop Customized Workflow

Step 1

Antigen/Antibody Sequence Analysis and CHAR Construct Design

Our expert team analyzes provided target HLA-peptide and antibody variable region sequences. We then design the optimal CHAR construct, integrating the single-chain variable fragment (scFv) to target the specific HLA-peptide complex, a robust transmembrane domain, and intracellular signaling domains for T-cell activation. This design minimizes off-target interactions.

Step 2

Gene Synthesis of the CHAR Construct

Following the design, the entire CHAR construct is custom-synthesized and cloned into a high-quality lentiviral expression vector. This step ensures high fidelity and prepares the construct for efficient viral packaging and cell transduction.

Step 3

Lentiviral Vector Packaging and Production

We proceed to generate high-titer, replication-defective lentiviral particles containing your CHAR construct. Our optimized packaging systems ensure efficient viral production, critical for robust transduction of target cells with minimal cytotoxicity.

Step 4

Cell Transduction and Expansion

Our service includes the transduction of client-provided T cells (or other specified immune cell types) with the generated lentiviral vectors. Following transduction, the CHAR-expressing cells are expanded under optimal conditions to achieve desired cell numbers and viability, ready for your downstream applications.

Step 5

Functional Validation and Quality Control

The final and crucial step involves comprehensive validation of the engineered CHAR-expressing cells. We assess CHAR expression levels via flow cytometry, evaluate the CHAR's binding affinity to the specific HLA-peptide target, and perform in vitro functional assays (e.g., cytotoxicity assays against target cells, cytokine release assays) to confirm potent and specific immune responses.

Attractive Advantages

Creative Biolabs' CHAR Construction Service offers distinct advantages designed to empower your research and therapeutic development.

Enhanced specificity for HLA-peptide complexes.
Reduced off-target effects
Rapid development timelines
Unparalleled customizability

Customer Reviews

Excellent

Unparalleled Specificity

Using Creative Biolabs' CHAR Construction Service in our research has significantly improved our ability to develop T-cell therapies with precise HLA-restricted targeting, circumventing the broad reactivity issues we previously faced with conventional CARs. The engineered cells exhibited exceptional on-target activity and minimal off-target effects, which is crucial for our therapeutic goals.

March 2025, Dr. S***n A 20 Likes

Excellent

Customization & Expertise

We had a unique HLA-peptide target, and Creative Biolabs' team demonstrated exceptional expertise in designing a custom CHAR construct that perfectly matched our requirements. The consultative approach and detailed reports were invaluable, providing us with a clear understanding of the construct design and validation. Their service far exceeded our expectations compared to previous collaborations.

April 2025, Prof. D***l R 5 Likes

FAQs

Q1: How does Creative Biolabs ensure the specificity and efficacy of the constructed CHARs?

A1: Our commitment to quality is unwavering. Creative Biolabs employs rigorous functional validation protocols, including assessing CHAR expression levels, specific antigen binding affinity, and downstream signaling pathways. We also conduct comprehensive in vitro functional assays, such as cytotoxicity assays against target cells and cytokine release analyses, to confirm potent and specific immune responses. For detailed validation protocols and quality control measures, please inquire with our team.

Q2: Can Creative Biolabs accommodate custom HLA-peptide targets for CHAR construction?

A2: Absolutely! Our Chimeric HLA Antibody Receptor construction service is designed with high customizability in mind. We actively collaborate with our clients to design and engineer CHARs against a wide range of unique HLA-peptide targets, leveraging our extensive experience in antibody engineering and advanced cell therapy design. Share your specific target details with us to discuss a tailored solution that meets your research objectives.

Work with Creative Biolabs

Creative Biolabs' CHAR construction service provides a cutting-edge solution for developing highly specific and potent cell therapies. By leveraging our deep expertise in immunology and genetic engineering, we deliver meticulously designed and validated CHAR constructs that address the critical need for precise targeting, offering enhanced safety and efficacy in challenging disease areas. Partner with us to accelerate your immunotherapy breakthroughs.

Reference

Ramírez-Chacón, Alejandro et al. "Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments." Frontiers in immunology vol. 13 932559. 12 Sep. 2022, doi:10.3389/fimmu.2022.932559. Distributed under Open Access License CC BY 4.0, without modification.